POLK rs111584802: Genetic Risk and Clinical Evidence
The genetic variant rs111584802 is a single-nucleotide polymorphism located within the POLK gene on chromosome 5. Pathogenic variation in this gene impairs specialized DNA repair processes and has been linked to health predispositions, notably prostate cancer susceptibility and rare neurodevelopmental disorders. Because rs111584802 is extremely rare in general populations, scientific understanding of its exact penetrance and medical impact continues to evolve.
What each genotype means
Typical POLK genotype
This is the most common genotype for this variant in the general population. Research indicates that this version of the POLK gene is considered the reference sequence, and it is not associated with the specific pathogenic risks linked to the G allele.
This is the most common genotype found across all major ancestral populations.
Heterozygous carrier status
You carry one copy of the reference allele and one copy of the G allele. While the G allele has been identified in clinical databases as potentially pathogenic regarding prostate cancer susceptibility, carrying a single copy does not necessarily indicate a clinical diagnosis. You should discuss your family history and any relevant screening needs with a healthcare professional.
This genotype is rare, occurring in less than 1% of the general population.
Increased risk variant
You carry two copies of the G allele, which has been classified in clinical databases as pathogenic and associated with an increased risk for malignant tumors of the prostate. This finding should be interpreted in the context of your overall health and family history. Please consult with a genetic counselor or your physician to discuss appropriate cancer screening strategies.
This genotype is very rare, observed in a very small fraction of the global population.
Genomic Location and Variant Characteristics
The variant rs111584802 is an uncommon single-nucleotide polymorphism situated on the short arm of human chromosome 5 within the POLK gene. According to genomic reference assemblies like GRCh38, the site corresponds to position 75,587,055, where the standard reference allele is adenine (A) and the alternate variant allele is guanine (G). In genetic databases such as dbSNP and ClinVar, this transition represents an alteration within the translesion synthesis machinery. Because coding variations in POLK can modify the amino acid sequence or transcript regulation of the enzyme, researchers examine such alleles to determine whether they impair structural folding, active site geometry, or regulatory domains. In public repositories like ClinVar, rs111584802 has been indexed in relation to malignant neoplasm of the prostate, marking it as a variant of clinical interest among oncologists and geneticists studying cancer predisposition.
Biological Role of the POLK Gene
The POLK gene encodes DNA polymerase kappa (pol κ), an evolutionary conserved enzyme belonging to the Y-family of specialized DNA polymerases. Unlike standard replicative polymerases, pol κ lacks 3-prime to 5-prime exonuclease proofreading capability and specializes in translesion DNA synthesis (TLS). TLS is an essential genome preservation mechanism that allows the cellular replication machinery to bypass bulky, disruptive DNA lesions—such as abasic sites and chemical adducts—that would otherwise stall replication forks and induce lethal double-strand breaks. In cellular models, a functional loss of POLK leads to compromised genomic stability and heightened vulnerability to oxidative stress and mutagenic damage. However, because TLS enzymes operate with lower replication fidelity on undamaged templates, altered pol κ activity can inadvertently promote base substitutions or frameshifts, creating a complex balance between cellular survival and mutation accumulation.
Associated Health Conditions and Research Evidence
Scientific investigations have associated pathogenic variation in POLK with both oncologic susceptibility and developmental phenotypes. ClinVar records list rs111584802 under hereditary predisposition to prostate cancer, reflecting evidence that defects in translesion synthesis and DNA repair can accelerate tumorigenesis in glandular prostate tissue. Broader clinical genetic databases like GeneCards and MalaCards also link severe functional disruptions of POLK to neurodevelopmental disorder with hypotonia, speech delay, and dysmorphic facies. However, the evidence connecting rs111584802 specifically to these outcomes is categorized as moderate rather than definitive. Much of the clinical attribution stems from targeted cohort analyses and cellular disruption studies. Because large-scale genome-wide association studies (GWAS) often lack statistical power to fully capture ultra-rare variants, further independent replication is needed to establish precise relative risk estimates for individual carriers.
Population Distribution and Frequency Patterns
Across worldwide reference populations cataloged in repositories such as gnomAD and the 1000 Genomes Project, rs111584802 is characterized as a rare variant. The minor allele frequency (MAF) remains well below one percent (MAF < 0.01) across diverse ancestral cohorts, meaning the vast majority of individuals carry two copies of the common reference allele (A). Because the alternate G allele is observed so infrequently, homozygous carriers (GG) are exceedingly rare in population databases. This scarcity implies that population-level screening panels rarely encounter the variant outside of specialized hereditary cancer panels or comprehensive clinical whole-exome sequencing. Due to the limited number of detected carriers globally, ancestry-specific allele frequencies have not yet shown marked geographic concentration, and estimates of risk must be interpreted with caution until larger multi-ancestry cohorts are profiled.
Navigating Results and Clinical Next Steps
Discovering an atypical genotype at rs111584802 via direct-to-consumer testing or clinical sequencing should not be regarded as a medical diagnosis. Genetic predisposition variants indicate statistical odds across populations, not an inevitable development of cancer or neurodevelopmental disorders. Unaccredited commercial arrays can occasionally produce false positives on rare loci, making clinical-grade confirmatory testing essential before making decisions. Individuals who possess personal or familial histories of prostate cancer or complex developmental delays should discuss their comprehensive pedigree with a certified genetic counselor or physician. A genetics professional can interpret variants in the context of established clinical guidelines, recommend validated screening protocols, and help families separate validated high-penetrance risk factors from emerging research observations.
How common is this variant?
The rs111584802 alternate allele is classified as rare, exhibiting a minor allele frequency (MAF) of less than 0.01 across global reference populations in gnomAD, with the AA genotype predominating universally.
Frequently asked questions
What does a rare variant in POLK indicate?
A rare variant in the POLK gene indicates an alteration in the blueprint for DNA polymerase kappa, an enzyme that assists with translesion DNA repair. Depending on the exact alteration, it may moderately increase biological susceptibility to certain conditions like prostate cancer, but it is not a direct disease diagnosis.
Does having the rs111584802 variant mean I will get prostate cancer?
No, having the variant does not guarantee that prostate cancer will occur. Complex diseases are influenced by many genes, age, lifestyle, and environmental exposures, and research on rs111584802 reflects statistical associations rather than certain outcomes.
How common is rs111584802 in the general population?
The variant is very rare worldwide, with a minor allele frequency of less than 1% across major ancestral groups in gnomAD. Almost all individuals inherit two copies of the standard A allele.
Should I change my medical care if I carry the variant allele?
You should not alter any medication, clinical routine, or screening plan without professional medical guidance. If you carry a variant of interest, consult a doctor or genetic counselor to review your family history and decide if standard preventive screening is appropriate.
Sources & further reading
Educational information only, last refreshed 9/12/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs111584802?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29